ClinicalTrials.gg
RecruitingNCT06634121LEAFLET IUpdated Oct 9, 2024

Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population

An interventional study of Transcatheter mitral valve edge-to-edge repair (M-TEER) in Mitral Regurgitation, Valvular Heart Disease and Heart Failure, sponsored by LMU Klinikum. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by LMU Klinikum · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2024, registered Aug 2024).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
17th of 48
180 · median 113
Started
2024
with 3 others
No phase
39 of 81
12 open now
Primary completion
2027-04
later than 15 of 31 live
Registered
73rd of 81
by date
Lead sponsor
3 of 81
LMU Klinikum

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 17th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2024, is one of 39 with no phase, reaches primary completion later than 15 of the 31 other live ones, and was the 73rd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

To investigate potential differences in procedural outcomes of both commercially available transcatheter edge-to-edge mitral valve repair devices in a non-selected clinical setting.

Read the detailed description

In the context of M-TEER, two different systems (MitraClip vs. PASCAL) are CE certified and clinically available. In the case of non-complex anatomy, both systems are comparable in terms of effectiveness. Whether this holds true in cases of complex or highly complex anatomy in an "Allcomer patient population" is currently unclear.

03

Conditions studied

  • Mitral Regurgitation
  • Valvular Heart Disease
  • Heart Failure

Keywords

  • Mitral Regurgitation
  • TEER
  • MitraClip
  • PASCAL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age equal or above 18 years
  • Written consent
  • Heart Team recommends M-TEER

Exclusion criteria

Exclusion Criteria:

  • Mitral Stenosis (MV mean PG > 5 mmHg)
  • Cardiogenic shock or hemodynamic instability at the time of intervention
  • Active endocarditis
  • Participant in another interventional cardiology study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    MitraClip

    Device: Transcatheter mitral valve edge-to-edge repair (M-TEER)

  • Active comparator
    PASCAL

    Device: Transcatheter mitral valve edge-to-edge repair (M-TEER)

Interventions

  • DeviceTranscatheter mitral valve edge-to-edge repair (M-TEER)

    M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.

06

What researchers measure

Primary outcomes

  1. Postprocedural residual MR measured by 3D EROA

    residual MR measured by 3D EROA as continuous parameter

    Time frame: During the index procedure

Secondary outcomes

  1. Reduction in MR EROA

    Reduction in MR EROA from baseline to postprocedural (relative and absolut value)

    Time frame: During the index procedure

  2. Comparing EROA in complex vs. non-complex patients

    Evaluation according to EROA reduction

    Time frame: During the index procedure

  3. Postprocedural MV opening area

    Postprocedural MV opening area (planimetric)

    Time frame: During the index procedure

  4. Postprocedural MV inflow gradient

    Mean pressure gradient and pressure halftime

    Time frame: During the index procedure

  5. SLDA

    Single Leaflet Device Attachment

    Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up

  6. Conversion to surgery or re-imaging of the MV

    Conversion to surgery (urgently or elective) or re-imaging of the MV

    Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up

  7. Stratification by MR etiology

    Primary vs. Secondary MR

    Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up

  8. Combined endpoint of mortality, repeat MV intervention or HHF

    Assessed at 30-days and 1-year

    Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up

  9. Quality of Life

    Measured using the KCCQ Score

    Time frame: At 30-day follow-up and at 1-year follow-up

  10. Exertional dyspnea

    NYHA functional class

    Time frame: At 30-day follow-up and at 1-year follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Oct 9, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06634121
Lead sponsor
LMU Klinikum
Responsible party
Prof. Dr. med. Jörg Hausleiter (Deputy chief, LMU Klinikum) — Principal investigator
First posted
Oct 9, 2024
Start date
Apr 1, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 9, 2024

Study contacts

Jörg Hausleiter, Prof. Dr.
Contact
Joerg.Hausleiter@med.uni-muenchen.de
+4989440072361
Ludwig Weckbach, PD Dr.
Contact
Ludwig.Weckbach@med.uni-muenchen.de
Jörg Hausleiter, Prof. Dr.
principal investigator · LMU Klinikum
Ludwig Weckbach, PD Dr.
principal investigator · LMU Klinikum

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion